Aura intends to use the proceeds from this financing to advance the clinical development of its VDC technology platform, including the pivotal Phase 3 program for AU-011, the Company's lead candidate in development for the first line treatment of choroidal melanoma, and ongoing research for additional programs in ocular oncology, as well as expanding the VDC technology into bladder cancer, the first non-ophthalmic solid tumor indication.

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

85 Bolton St.
Cambridge, MA 02140
USA

Phone

(617) 401-3360

Website

www.aurabiosciences.com

Email Address

[email protected]

Overview

Aura Biosciences is developing a new class of therapies to target and selectively destroy tumor cells. Its lead program in ocular melanoma, developed under a CRADA with the National Cancer Institute (NCI), has been granted orphan drug status by the US Food and Drug Administration.

Profile

Social Media

Aura Biosciences Company Twitter Account

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Elisabet de los Pinos

Chief Financial Officer

Julie Feder

Chief Medical Officer

Cadmus Rich

Browse more venture capital transactions:

Prev: 3/23/2021: Connected2Fiber venture capital transaction
Next: 3/23/2021: Evidation Health venture capital transaction

Share this article

Where The Data Comes From

We record all VC transactions involving tech companies. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary